Amnesteem

This page contains recent news articles, when available, and an overview of Amnesteem but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.


Overview:

Amnesteem
(when available)

Pharmacology and use:
Tretinoin, also known as all-trans-retinoic acid (ATRA), is a naturally occurring derivative of vitamin A (retinol). Retinoids such as tretinoin are important regulators of cell reproduction, proliferation, and differentiation and are used to treat acne and photodamaged skin and to manage keratinization disorders such as ichthyosis and keratosis follicularis. Tretinoin also represents the class of anticancer drugs called differentiating agents and is used in the treatment of acute promyelocytic leukemia (APL). For the the induction of remission in patients with acute promyelocytic leukemia (APL), French-American-British (FAB) classification M3 (including the M3 variant); For the topical treatment of acne vulgaris, flat warts and other skin conditions (psoriasis, ichthyosis congenita, icthyosis vulgaris, lamellar icthyosis, keratosis palmaris et plantaris, epidermolytic hyperkeratosis, senile comedones, senile keratosis, keratosis follicularis (Darier's disease), and basal cell carcinomas.); For palliative therapy to improve fine wrinkling, mottled hyperpigmentation, roughness associated with photodamage.

Mechanism Of Action:
Tretinoin binds to alpha, beta, and gamma retinoic acid receptors (RARs). RAR-alpha and RAR-beta have been associated with the development of acute promyelocytic leukemia and squamous cell cancers, respectively. RAR-gamma is associated with retinoid effects on mucocutaneous tissues and bone. Although the exact mechanism of action of tretinoin is unknown, current evidence suggests that the effectiveness of tretinoin in acne is due primarily to its ability to modify abnormal follicular keratinization. Comedones form in follicles with an excess of keratinized epithelial cells. Tretinoin promotes detachment of cornified cells and the enhanced shedding of corneocytes from the follicle. By increasing the mitotic activity of follicular epithelia, tretinoin also increases the turnover rate of thin, loosely-adherent corneocytes. Through these actions, the comedo contents are extruded and the formation of the microcomedo, the precursor lesion of acne vulgaris, is reduced. Tretinoin is not a cytolytic agent but instead induces cytodifferentiation and decreased proliferation of APL cells in culture and in vivo. When Tretinoin is given systemically to APL patients, tretinoin treatment produces an initial maturation of the primitive promyelocytes derived from the leukemic clone, followed by a repopulation of the bone marrow and peripheral blood by normal, polyclonal hematopoietic cells in patients achieving complete remission (CR). The exact mechanism of action of tretinoin in APL is unknown.

News Articles on Tretinoin

Ennis & Ennis, PA is Still Accepting Accutane Cases against Hoffman La-Roche  -  ‎Oct 26, 2009‎
The generic versions of the drug are Sotret, Claravis and Amnesteem. Ennis states, "The generic drug makers have the same duty to warn as La-Roche, ... The Open Press (press release)

Buy Accutane  -  ‎Oct 31, 2009‎
Amnesteem did you know how i felt when in abundance. Although he or other healthcare professional. Accordingly the Panel concludes the simply remain until ... Newstalk ZB

Accutane pulled from market  -  ‎Jul 9, 2009‎
Accutane contains the drug isotretinoin, which is also available in Amnesteem from Genpharm and Mylan, Claravis from Teva-Barr, and Sotret from Ranbaxy. Examiner.com

Accutane in the News  -  ‎Jul 6, 2009‎
Other generic versions of Accutane (isotretinoin), including Amnesteem and Claravis, will still be available. According to Roche Holding AG, About - News & Issues

Ocean Tomo’s www.PatentBidAsk.com Features Patents Available for ...  -  Jul 8, 2008
...also referred to as Isotretinoin which is a form of vitamin A sold under various global tradenames, such as Accutane®, Sotret®, Amnesteem®, Oratane®, Business Wire (press release),

Brand Names/Synonyms:
Amnesteem is also known by the following brand names and/or synonyms:
Aberel; Accutane; Airol; Aknefug; Aknoten; All Trans Retinoic Acid; All Trans-Retinoic Acid; Amnesteem; Avita; Beta-Retinoic Acid; Claravis; Dermairol; Eudyna; Isotretinoin; Lsotretinoin; Panretin; Renova; Retin-A; Retin-a Micro; Retinoate; Retinoic Acid; Retinoic Acid, All Trans Isomer; Retionic Acid; Retisol-A; Solage; Sotret; Stieva-A; Stieva-a Forte; Trans-Retinoic Acid; Tretin M; Tretinoin; Tri-Luma; Vesanoid; Vitamin a Acid; Vitinoin; β-Retinoic Acid

Drug Category:
Amnesteem is categorized under the following by the FDA: Keratolytic Agents; Antineoplastic Agents; Cell Stimulants and Proliferants (84:16.00); ATC:D10AD01; ATC:D10AD04; ATC:D10BA01; ATC:L01XX14; ATC:L01XX22

Dosage Forms:
CAPSULE; CREAM; GEL; LIQUID

Absorption:
1-31% (topical);

Interactions:
[an error occurred while processing this directive]



Chemical IUPAC Name:
3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)-nona-2,4,6,8-tetraenoic acid





Health Home | Conditions | Cancer | Medications | Surgery | Vaccines


The Cancer News Network


Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.



COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy